WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise Researchers at Washington University School of Medicine in St. Louis have ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...